Abstract
Severe psoriasis is associated with significant cardiovascular mortality. We therefore investigated the effects of systemic therapy on the cardiovascular risk of psoriasis patients. Thirteen consecutive patients receiving fumaric acid esters were included and followed for 24 weeks both clinically and by means of laboratory monitoring, 10 completed the study. Eight of ten patients showed a PASI-50 response. Two of three patients with clinical insulin resistance (Homeostasis Model Assessment of insulin resistance >2.5) showed normal insulin responsiveness at the end of the study. Clinical improvement was paralleled by a reduction of high-sensitive CRP serum levels (median −25%). There was a trend toward reduced serum levels for the vascular endothelial growth factor (median −10%) and resistin (median −4%), while the potentially cardio-protective adiponectin showed a trend toward increased serum levels under therapy (median +19%). Systemic endothelial function assessed by venous occlusion plethysmography revealed an improvement of endothelial vasodilator function after 24 weeks of treatment (p < 0.02). This is the first prospective study documenting an amelioration of endothelial cell function in patients with moderate-to-severe plaque-type psoriasis under effective continuous systemic therapy. Future studies need to compare the cardioprotective effects of different treatment modalities, based on hard end points such as the rate of myocardial infarction.
Similar content being viewed by others
References
Berth-Jones J, Grotzinger K, Rainville C, Pham B, Huang J, Daly S, Herdman M, Firth P, Hotchkiss K (2006) A study examining inter- and intrarater reliability of three scales for measuring severity of psoriasis: Psoriasis Area and Severity Index, Physician’s Global Assessment and Lattice System Physician’s Global Assessment. Br J Dermatol 155:707–713
Boehncke W-H, Boehncke S, Schön MP (2010) Managing comorbid disease in patients with psoriasis. BMJ 340:b5666
Boehncke S, Thaci D, Beschmann H, Ludwig RJ, Ackermann H, Badenhoop K, Boehncke WH (2007) Psoriasis patients show signs of insulin resistance. Br J Dermatol 157:1249–1251
Cerman AA, Bozkrut S, Sav A, Tulunay A, Elbasi MO, Ergun T (2008) Serum leptin levels, skin leptin and leptin receptor expression in psoriasis. Br J Dermatol 159:820–826
Coimbra S, Oliveira H, Reis F, Belo L, Rocha S, Quintanilha A, Figueiredo A, Teixeira F, Castro E, Rocha-Peraira P, Santos-Silva A (2010) C-reactive protein and leucocyte activation in psoriasis vulgaris according to severity and therapy. J Eur Acad Dermatol 24:789–796
Dixon WG, Watson KD, Lunt M, Hyrich KL, the British Society for Rheumatology Biologics Register Control Centre Consortium (2007) Reduction in the incidence of myocardial infarction in patients with rheumatoid arthritis who respond to anti-tumor necrosis factor alpha therapy: results from the British Society for Rheumatology Biologics Register. Arthritis Rheum 56:2905–2912
Fichtlscherer S, Rossig L, Breuer S et al (2001) Tumor necrosis factor antagonism with etanercept improves systemic endothelial vasoreactivity in patients with advanced heart failure. Circulation 104:3023–3025
Fichtlscherer S, Rosenberger G, Walter DH, Breuer S, Dimmeler S, Zeiher AM (2000) Elevated C-reactive protein levels and impaired endothelial vasoreactivity in patients with coronary artery disease. Circulation 102:1000–1006
Finlay AY (2005) Current severe psoriasis and the rule of tens. Br J Dermatol 152:861–867
Garbaraviciene J, Diehl S, Varwig D, Bylaite M, Ackermann H, Ludwig RJ, Boehncke WH (2010) Platelet P-selectin reflects a state of cutaneous inflammation: possible application to monitor treatment efficacy in psoriasis. Exp Dermatol 19:736–741
Gelfand JM, Neimann AL, Shin DB, Wang X, Margolis DJ, Troxel AB (2006) Risk of myocardial infarction in patients with psoriasis. JAMA 296:1735–1741
Gelfand JM, Troxel AB, Lewis JD, Kurd SK, Shin DB, Wang X, Margolis DJ, Strom BL (2007) The risk of mortality in patients with psoriasis: results from a population-based study. Arch Dermatol 143:1493–1499
Gisondi P, Fantin F, Del Giglio M, Valbusa F, Marino F, Zamboni M, Girolomoni G (2009) Chronic plaque psoriasis is associated with increased arterial stiffness. Dermatology 218:100–103
Hansson GK (2005) Inflammation, atherosclerosis, and coronary artery disease. NEJM 352:1685–1695
Hürlimann D, Forster A, Noll G et al (2002) Anti-tumor necrosis factor-alpha treatment improves endothelial function in patients with rheumatoid arthritis. Circulation 106:2184–2187
Jacobsson LT, Turesson C, Nilsson JA, Petersson IF, Lindqvist E, Saxne T, Geborek P (2007) Treatment with TNF blockers and mortality risk in patients with rheumatoid arthritis. Ann Rheum Dis 66:670–675
Jansson PA (2007) Endothelial dysfunction in insulin resistance and type 2 diabetes. J Int Med 262:173–183
Kearney MT, Duncan ER, Kahn M, Wheatcroft SB (2008) Insulin resistance and endothelial cell dysfunction; studies in mammalian models. Exp Physiol 93:158–163
Kimball AB, Gladman D, Gelfand JM, Gordon K, Horn EJ, Korman NJ, Korver G, Krueger GG, Strober BE, Lebwohl MG (2008) National Psoriasis Foundation clinical consensus on psoriasis comorbidities and recommendations for screening. J Am Acad Dermatol 58:1031–1042
Lazar MA (2001) The hormone resistin links obesity to diabetes. Nature 409:307–312
Ludwig RJ, Herzog C, Rostock A, Ochsendorf FR, Zollner TM, Thaci D, Kaufmann R, Vogl TJ, Boehncke WH (2007) Psoriasis: a possible risk factor for development of coronary artery calcification. Br J Dermatol 156:271–276
Ludwig RJ, Schultz JE, Boehncke WH, Podda M, Tandi C, Krombach F, Baatz H, Kaufmann R, von Andrian UH, Zollner TM (2004) Activated, not resting, platelets increase leukocyte rolling in murine skin utilizing distinct sets of adhesion molecules. J Invest Dermatol 122:830–836
Martyn-Simmons CL, Ranawaka RR, Chowienczyk P, Crook MA, Marber MS, Smith CH, Barker JN. A prospective case controlled cohort study of endothelial function in patients with moderate to severe psoriasis. Br J Dermatol (e-pub ahead of print)
Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC (1985) Homeostasis model assessment: insulin resistance and β-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 28:412–419
Melander O, Newton-Cheh C, Almgren P, Hedblad B, Berglund G, Engström G, Persson M, Smith JG, Magnusson M, Christensson A, Struck J, Morgenthaler NG, Bergmann A, Pencina MJ, Wang TJ (2009) Novel and conventional biomarkers for prediction of incident cardiovascular events in the community. JAMA 302:49–57
Nast A, Kopp I, Augustin M, Banditt KB, Boehncke WH, Follmann M, the Psoriasis Treatment Guideline Expert Group (2007) German evidence-based guidelines for the treatment of psoriasis vulgaris (short version). Arch Dermatol Res 299:111–138
Nestle FO, Kaplan DH, Barker JNWN (2009) Psoriasis. NEJM 361:496–509
Prodanovich S, Ma F, Taylor JR, Pezon C, Fasihi T, Kirsner RS (2005) Methotrexate reduces incidence of vascular diseases in veterans with psoriasis or rheumatoid arthritis. J Am Acad Dermatol 52:262–267
Reich K, Mrowitz U (2007) Treatment goals in psoriasis. J Dtsch Dermatol Ges 5:566–574
Schächinger V, Britten MB, Zeiher AM (2000) Prognostic impact of coronary vasodilator dysfunction on adverse long-term outcome of coronary heart disease. Circulation 101:1899–1906
Stern RS (2010) Psoriasis is not a useful independent risk factor for cardiovascular disease. J Invest Dermatol 130:917–919
Soeki T, Tamura Y, Shinohara H, Tanaka H, Bando K, Fukuda N (2000) Serial changes in serum VEGF and HGF in patients with acute myocardial infarction. Cardiology 93:168–174
Strober B, Teller C, Yamauchi P, Miller JL, Hooper M, Yang YC, Dann F (2008) Effects of etanercept on C-reactive protein levels in psoriasis and psoriatic arthritis. Br J Dermatol 159:322–330
Ulusoy RE, Karabudak O, Yokusoglu M, Kilicaslan F, Kirilmaz A, Cebeci BS (2010) Noninvasive assessment of impaired endothelial function in psoriasis. Rheumatol Int 30:479–483
Walsh K (2009) Adipokines, myokines and cardiovascular disease. Circ J 73:13–18
Weikert C, Westphal S, Berger K, Dierkes J, Möhlig M, Spranger J, Rimm EB, Willich SN, Boeing H, Pischon T (2008) Plasma resistin levels and risk of myocardial infarction and ischemic stroke. J Clin Endocrinol Metab 93:2647–2653
Weisenseel P, Kuznetsov AV, Prinz JP (2007) Implementation of the S3-guidelines for systemic and UV therapy of moderate to severe psoriasis vulgaris by an algorithm. JDDG 5:683–688
Related articles recently published in Archives of Dermatological Research (selected by the journal’s editorial staff)
Bissonnette R, Langley RG, Papp K, Matheson R, Toth D, Hultquist M, Geba GP, White B (2009) Humanized anti-CD2 monoclonal antibody treatment of plaque psoriasis: efficacy and pharmacodynamic results of two randomized, double-blind, placebo-controlled studies of intravenous and subcutaneous siplizumab. Arch Dermatol Res 301:429–442
Ma LJ, You Y, Bai BX, Li YZ (2009) Therapeutic effects of heme oxygenase-1 on psoriasiform skin lesions in guinea pigs. Arch Dermatol Res 301:459–466
Morsy H, Kamp S, Thrane L, Behrendt N, Saunder B, Zayan H, Elmagid EA, Jemec GB (2010) Optical coherence tomography imaging of psoriasis vulgaris: correlation with histology and disease severity. Arch Dermatol Res 302:105–111
Mrowietz U, Kragballe K, Reich K, Spuls P, Griffiths CE, Nast A, Franke J, Antoniou C, Arenberger P, Balieva F, Bylaite M, Correia O, Dauden E, Gisondi P, Iversen L, Kemeny L, Lahfa M, Nijsten T, Rantanen T, Reich A, Rosenbach T, Segaert S, Smith C, Talme T, Volc-Platzer B, Yawalkar N (2010) Definition of treatment goals for moderate to severe psoriasis: a European consensus. Arch Dermatol Res. doi:10.1007/s00403-010-1080-1
Munz OH, Sela S, Baker BS, Griffiths CE, Powles AV, Fry L (2010) Evidence for the presence of bacteria in the blood of psoriasis patients. Arch Dermatol Res 302:495–498
Nancy AL, Yehuda S (2009) Prediction and prevention of autoimmune skin disorders. Arch Dermatol Res 301:57–64
O’Daly JA, Lezama R, Gleason J (2009) Isolation of Leishmania amastigote protein fractions which induced lymphocyte stimulation and remission of psoriasis. Arch Dermatol Res 301:411–427
Prpic-Massari L, Kastelan M (2009) Innate and acquired immunity in psoriasis. Arch Dermatol Res 301:195–196
Rostami-Yazdi M, Clement B, Mrowietz U (2010) Pharmacokinetics of anti-psoriatic fumaric acid esters in psoriasis patients. Arch Dermatol Res 302:531–538
Acknowledgments
This study was supported by a research grant from Biogen Idec. JG was supported by a fellowship sponsored by Centocor.
Conflict of interest
DT and WHB received honoraria as speakers on the occasion of symposia sponsored by the following companies: Abbott, Biogen Idec, Essex, Wyeth.
Author information
Authors and Affiliations
Corresponding author
Additional information
S. Boehncke and S. Fichtlscherer contributed equally to this project.
Rights and permissions
About this article
Cite this article
Boehncke, S., Fichtlscherer, S., Salgo, R. et al. Systemic therapy of plaque-type psoriasis ameliorates endothelial cell function: results of a prospective longitudinal pilot trial. Arch Dermatol Res 303, 381–388 (2011). https://doi.org/10.1007/s00403-010-1108-6
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00403-010-1108-6